Title
Treatment of Latent Tuberculosis Infection—An Update
Date Issued
01 December 2019
Access level
open access
Resource Type
review
Author(s)
Huaman M.A.
Sterling T.R.
Publisher(s)
W.B. Saunders
Abstract
Treatment of latent tuberculosis infection (LTBI) is an important component of TB control and elimination. LTBI treatment regimens include once-weekly isoniazid plus rifapentine for 3 months, daily rifampin for 4 months, daily isoniazid plus rifampin for 3–4 months, and daily isoniazid for 6–9 months. Isoniazid monotherapy is efficacious in preventing TB disease, but the rifampin- and rifapentine-containing regimens are shorter and have similar efficacy, adequate safety, and higher treatment completion rates. Novel vaccine strategies, host immunity-directed therapies and ultrashort antimicrobial regimens for TB prevention, such as daily isoniazid plus rifapentine for 1 month, are under evaluation.
Start page
839
End page
848
Volume
40
Issue
4
Language
English
OCDE Knowledge area
Ciencias de la salud
Enfermedades infecciosas
Scopus EID
2-s2.0-85074765486
PubMed ID
Source
Clinics in Chest Medicine
ISSN of the container
02725231
Sponsor(s)
Financial Support: This work was supported in part by the National Center for Advancing Translational Sciences (KL2 TR001426 to M.A. Huaman). The content is solely the responsibility of the authors and does not represent the official views of the National Institutes of Health or the institutions with which the authors are affiliated.
Sources of information:
Directorio de Producción Científica
Scopus